We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Figure 2

Figure 2. From: Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission.

All treatments tested show very low propensity to induce catalepsy. Each bar represents the median catalepsy score±semi-interquartile range, measured at 60 min, based on observations of eight animals per treatment group. ++p<0.01, +++p<0.001 vs saline+vehicle.

Monica M Marcus, et al. Neuropsychopharmacology. 2010 August;35(9):1952-1961.
2.
Figure 4

Figure 4. From: Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission.

Reboxetine enhances the effect of a sub-maximal concentration of olanzapine on NMDA-induced currents in pyramidal cells. Bar representing the effects of reboxetine 20 nM, olanzapine 3 nM and the combination of reboxetine 20 nM and olanzapine 3 nM on NMDA induced currents in pyramidal cells of the mPFC. The results are presented as mean±SEM. ++p<0.05, +++p<0.001 compared with baseline, ***p<0.001 between different treatments.

Monica M Marcus, et al. Neuropsychopharmacology. 2010 August;35(9):1952-1961.
3.
Figure 3

Figure 3. From: Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission.

Reboxetine enhances the olanzapine-induced dopamine output in the mPFC, but not in the NAC. The effects of olanzapine 1.25 mg/kg i.p. administration on dopamine output in the mPFC (a, b) and NAC (c, d) respectively, in rats pretreated with saline or reboxetine 6 mg/kg (i.p.). Figures (a and c) show the effects on dopamine output over time in mPFC and NAC, respectively. Arrows indicate time of reboxetine/saline and olanzapine/vehicle injections. *p<0.05, **p<0.01, ***p<0.001 compared with baseline. Figures (b and d) show the overall dopamine output (AUC), measured for 60–240 min (mPFC) and 45–240 min (NAC). The dotted line represents the baseline values (100%). The results are presented as mean±SEM. ++p<0.01, +++p<0.001 compared with control group (saline/vehicle); **p<0.01, ***p<0.001 between different treatments.

Monica M Marcus, et al. Neuropsychopharmacology. 2010 August;35(9):1952-1961.
4.
Figure 1

Figure 1. From: Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission.

Reboxetine enhances the effect of a low, but not a high, dose of olanzapine on suppression of CAR. Effects on CAR behavior in rats at (a) 20 min and (b) 90 min after administration of vehicle, olanzapine 1.25 or olanzapine 2.5 mg/kg i.p. in combination with saline or reboxetine 6 mg/kg i.p. (reboxetine/saline was administered 30 min before vehicle/olanzapine). The results are presented as median (% avoidance)±semi-interquartile range. Animals (n=10) are serving as their own control in a change-over design (Li, 1964). ++p<0.01 vs saline+vehicle, ##p<0.01 vs reboxetine+vehicle, *p<0.05 saline+olanzapine vs reboxetine+olanzapine.

Monica M Marcus, et al. Neuropsychopharmacology. 2010 August;35(9):1952-1961.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk